Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Significant Drop in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 1,307,493 shares, a decline of 51.2% from the February 12th total of 2,677,258 shares. Based on an average trading volume of 7,073,285 shares, the short-interest ratio is currently 0.2 days. Currently, 4.2% of the company’s shares are sold short. Currently, 4.2% of the company’s shares are sold short. Based on an average trading volume of 7,073,285 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

A number of research firms have recently commented on LIMN. Wall Street Zen lowered Liminatus Pharma from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Liminatus Pharma has an average rating of “Sell”.

Liminatus Pharma Stock Down 6.6%

Shares of NASDAQ:LIMN traded down $0.02 during midday trading on Thursday, reaching $0.24. 2,114,851 shares of the company were exchanged, compared to its average volume of 10,908,657. Liminatus Pharma has a fifty-two week low of $0.21 and a fifty-two week high of $33.66. The stock has a fifty day simple moving average of $0.63 and a two-hundred day simple moving average of $1.14. The firm has a market cap of $7.39 million and a PE ratio of -1.98.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.